BARD1 Life Sciences Limited 

BD1 presented its quarterly update report for the quarter ended on September 30, 2018, on October 31, 2018. BD1 continued with its plan to explore varied corporate and fundraising opportunities for further expansion of its product portfolio, diversification of its risk profile and enhancing shareholder value.

Moderate Financials: Thecompany has posted the closing cash balance at $1.13m at the end of the first quarter as on September 30, 2018. Net operating cash flow reported a drop of almost 74% up to $304k from $531k reported during the previous quarter. The drop of the net operating cash flow was contributed by research and development expenses on BARD1 pipeline of around $32k, $30k expenditure on patents and General administration expenses contributing to $242k.

Strong Intellectual property portfolio:Company holds a strong intellectual property position covering varied BARD1 DNA and protein sequences. The company has been granted with the Chinese patent for the core BARD1 patent family on September 28. BARD1 core patent family has total of 6 granted patents for now in the US, Japan, divisional Japan, China, Australia, China divisional, with other pending patents in line. The patent family provides the intellectual protection of the property for the BARD1 lung cancer test. Group’s BARD-1 Ovarian cancer test has also shown high diagnostic accuracy.

Technically, the scrip made a “Doji” candle on the price charts on October 29, touching the higher levels of $0.064 and lows of $0.045. The scrip is trading in between the higher zone and the mean deviation of the bollinger bands. Lately, the scrip has broken the low levels made on October 29 and made a new low of $0.036 and wrapped the session at the levels of $0.038, as at October 31, 2018 (down 19.2%). Major indicators like RSI still indicate for chances of some support and upside move in medium term.

The market cap of BD1 was recorded at $38.95bn; and at current juncture, scrip is trading at the price levels of $0. 038. Moderate financials with strong intellectual property portfolio, along with current price levels trading in between the high and mid bollinger band zone exhibit for a wait and watch view at the current price levels of $0.038.
 

Nuheara Limited 

NUH presented its quarterly update report for the quarter ended on September 30, 2018 on October 31, 2018.

Moderate Financials: Cash balance went up to $4.99 million during the quarter ended on September 30, 2018. 11.8% rise in the operating cash flow up to $2340k in Q1FY19 from $2653k in Q4FY18 was noted. Company received a tax rebate of $1920k for R&D and related activities. There was 30% fall in the receipts from the customers up to $661k in Q1FY9 from $864k as reported in Q1FY18 and $1333k for Q4FY18. 60% growth on year–on-year rebate represents strong commitment  of the company in the achievement of research leadership in the rapidly changing scenario of global hearing healthcare.

Healthy Business plan:NUH has made several decisions during the quarter, one such decision was to consolidate any high-end product sales to a more focussed and dedicated channel. Entry level products are still open to all retail space. This approach will allow the company to deploy its limited sales and marketing resources to more focussed group of global retailers and thereby helping in improving retail sale through rates.
Technically, the scrip is trading at the lower bollinger band zone with lower low formed on the price charts. Relative strength indicator reflected the stock being in an oversold zone. Some retracement may happen with support from volume and fundamental events.

The market cap of NUH was recorded at $65.08M. Moderate financials with decent business portfolio, along with current price levels trading in between the high and mid Bollinger band zone make NUH to be on our watchlist while it trades at the current price levels of $0.062, down 15.1% on October 31, 2018.
 
 

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.